Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Lonza Group AG / Key word(s): Miscellaneous Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly formed CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities The model comes into effect today, and is reflected on the updated website Basel, Switzerland, 1 April 2025 – Lonza has announced that its new simplified and streamlined o...
Lonza Group AG / Key word(s): Share Buyback Lonza Completes its Share Buyback Program 01.04.2025 / 07:00 CET/CEST Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through the program, Lonza repurchased 4,239,731 of its shares on a second trading line on the SIX Swiss Exchange for an average purchase price of CHF 471.7279 per share.The Board of Directors intends to use the capital band to cancel the shares repurchased under the share buyback program. More informa...
Four Directors at Merck Kgaa bought 12,756 shares at 130.607EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Major Low Likely in Place on S&P 500 In our 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, that one or two 8-10% pullbacks in a given year on the SPX is common (even during bull markets), and to not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers...
Sartorius Stedim Biotech SA / Mot-clé(s) : Assemblée générale Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A. 25-Mars-2025 / 15:35 CET/CEST Aubagne, le 25 mars 2025 Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A.Lors de l'Assemblée générale annuelle mixte de Sartorius Stedim Biotech S.A. qui s'est tenue aujourd'hui, les actionnaires à une large majorité ont donné décharge à tous les administrateurs.Les actionnaires ont élu Cécile Dussart et Christopher Nowers en tant que nouve...
Sartorius Stedim Biotech SA / Key word(s): AGM/EGM Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. 25-March-2025 / 15:35 CET/CEST Aubagne, France | March 25, 2025 Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority.The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed...
A director at Lonza Group AG bought 270 shares at 546.082CHF and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
A director at Thermo Fisher Scientific Inc sold/sold after exercising options 3,775 shares at 532.525USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.